deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT03076203

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

Sponsor: Bayer

Conditions Hormone-refractory Prostate Cancer Prostate Carcinoma Metastatic to the Bone Stage IV Prostate Adenocarcinoma
Interventions Niraparib Radium Ra 223 Dichloride
Updated 18 times since 2017 Last updated: Apr 28, 2025 Started: Sep 22, 2017 Primary completion: Jan 13, 2020 Completion: Nov 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hormone-refractory Prostate Cancer and Prostate Carcinoma Metastatic to the Bone and is currently completed. Bayer leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Apr 2019 · 10 months · monthly snapshot~Apr 2019 – ~Jul 2019 · 3 months · monthly snapshot~Jul 2019 – ~Mar 2020 · 8 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2022 · 18 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Nov 2023 · 11 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Feb 2026 · 9 months · monthly snapshot~Feb 2026 – present · 4 months · monthly snapshot

Change History

18 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1

  2. May 2025 — Feb 2026 [monthly]

    Completed PHASE1

  3. Sep 2024 — May 2025 [monthly]

    Completed PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  5. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE1

▶ Show 13 earlier versions

  1. Dec 2022 — Nov 2023 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Mar 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Jul 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  7. Apr 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  8. Jun 2018 — Apr 2019 [monthly]

    Recruiting PHASE1

  9. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. Oct 2017 — May 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  11. Aug 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1

  12. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE1

  13. Apr 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Janssen, LP
  • Prostate Cancer Clinical Trials Consortium
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations